Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trop-2 as a Therapeutic Target in Breast Cancer.
Sakach E, Sacks R, Kalinsky K. Sakach E, et al. Among authors: kalinsky k. Cancers (Basel). 2022 Nov 30;14(23):5936. doi: 10.3390/cancers14235936. Cancers (Basel). 2022. PMID: 36497418 Free PMC article. Review.
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou E, Gradishar WJ, Stringer-Reasor E, Reid SA, O'Dea A, O'Regan R, Crew KD, Hershman DL. Kalinsky K, et al. J Clin Oncol. 2023 Aug 20;41(24):4004-4013. doi: 10.1200/JCO.22.02392. Epub 2023 May 19. J Clin Oncol. 2023. PMID: 37207300 Clinical Trial.
CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
Sakach E, Keskinkilic M, Wood S, Canning M, Kalinsky K. Sakach E, et al. Among authors: kalinsky k. Curr Treat Options Oncol. 2023 Sep;24(9):1103-1119. doi: 10.1007/s11864-023-01109-9. Epub 2023 Jun 14. Curr Treat Options Oncol. 2023. PMID: 37314645 Review.
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.
Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A. Hecht JR, et al. Among authors: kalinsky k. ESMO Open. 2023 Apr;8(2):100884. doi: 10.1016/j.esmoop.2023.100884. Epub 2023 Feb 28. ESMO Open. 2023. PMID: 36863095 Free PMC article. Clinical Trial.
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, Che D, Nayar U, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Han HS, Iafrate AJ, Ryan LY, Juric D, Moy B, Ellisen LW, Maheswaran S, Wagle N, Haber DA, Bardia A, Wander SA. Brett JO, et al. Among authors: kalinsky k. JCO Precis Oncol. 2023 May;7:e2200532. doi: 10.1200/PO.22.00532. JCO Precis Oncol. 2023. PMID: 37141550 Free PMC article.
The role of immune checkpoint inhibition in triple negative breast cancer.
Tarekegn K, Keskinkilic M, Kristoff TJ, Evans ST, Kalinsky K. Tarekegn K, et al. Among authors: kalinsky k. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1095-1106. doi: 10.1080/14737140.2023.2265059. Epub 2023 Oct 26. Expert Rev Anticancer Ther. 2023. PMID: 37771270 Review.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. Among authors: kalinsky k. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.
Zeleke TZ, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez MJ, Honan E, Yang M, Chia PL, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi MS, Accordino M, Crew KD, Hershman DL, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Zeleke TZ, et al. Among authors: kalinsky k. Nat Cancer. 2023 Feb;4(2):257-275. doi: 10.1038/s43018-022-00489-5. Epub 2022 Dec 30. Nat Cancer. 2023. PMID: 36585452 Free PMC article.
166 results